Los Angeles Capital Management’s ClearPoint Neuro CLPT Stock Holding History

Los Angeles Capital Management’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,046	Closed	-$105K	–	1343
2022 Q1	$105K	Sell	10,046 -30	-0.3%	-$273	﹤0.01%	1385
2021 Q4	$113K	Sell	10,076 -114	-1%	-$1.71K	﹤0.01%	1368
2021 Q3	$181K	Hold	10,190	–	–	﹤0.01%	1433
2021 Q2	$195K	Buy	+10,190	New	+$197K	﹤0.01%	1494

Other funds holding CLPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Los Angeles Capital Management's CLPT Position: Q2 2022 in Review

Los Angeles Capital Management sold out of ClearPoint Neuro (CLPT) in Q2 2022, closing a stake of 10,046 shares — an estimated $105K sold.

Los Angeles Capital Management first reported a position in CLPT in Q2 2021 and held it in 4 quarters. The position peaked at $195K in Q2 2021. 50 funds tracked by Wall St. Rank hold CLPT as of Q2 2022.

Los Angeles Capital Management reported no remaining ClearPoint Neuro position as of Q2 2022 after selling out during the quarter.
Los Angeles Capital Management sold 10,046 ClearPoint Neuro shares in Q2 2022, an estimated $105K.
Los Angeles Capital Management first reported a position in ClearPoint Neuro in Q2 2021 and held it in 4 quarters.
Los Angeles Capital Management's ClearPoint Neuro position peaked at $195K in Q2 2021.
50 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2022.

Based on Los Angeles Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.